Nisha Amalaki Vati in uncontrolled type II Diabetes Mellitus.

Study the effect of nisha amalaki (as an adjuvant drug ) in uncontrolled type II diabetes mellitus a pragmatic randomised controlled trial.

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/04/051473

Enrollment

Registered

2023-04-11

Start date

Unknown

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications Health Condition 2: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: patients of T1DM of 30 to 70 years of age having HbA1C between 7 to 10%

Exclusion criteria

Exclusion criteria: known case of CHF, CKD,cirrohsis of liver pregnancy and lactation severely ill patients

Design outcomes

Primary

Measure	Time frame
to evaluate the effect on HbA1c and blood sugar level of fasting and post meal to evaluate the parameters reflecting oxidative stress i. malondialdehyde MDA product of membrane lipid peroxidation measured as thiobarbituric acid reactive substances TBARS II. superoxide dismutase SOD assayTimepoint: 0 day 15th day 30th day 45th day 60th day	—

Secondary

Measure	Time frame
to classify the patients as per their prakriti by prakriti assesment scale and sthula and krushpramehi by BMI to evaluate the effect on CBC LFT KFT and lipid profile and any adverse effectTimepoint: 0 day 15th day 30th day 45th day 60th day	—

Countries

India

Contacts

Public ContactDr Shweta Parwe

mahatma gandhi ayurveda college hospital and research centre salod wardha

shweta.parwe@dmimsu.edu.in9403142270

Outcome results